Overview

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Status:
Not yet recruiting
Trial end date:
2023-08-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company